WO2023126672 - METHOD AND DEVICE FOR REMOVAL OF CIRCULATING CELL FREE DNA
National phase entry is expected:
Publication Number
WO/2023/126672
Publication Date
06.07.2023
International Application No.
PCT/IB2022/000665
International Filing Date
21.10.2022
Title **
[English]
METHOD AND DEVICE FOR REMOVAL OF CIRCULATING CELL FREE DNA
[French]
PROCÉDÉ ET DISPOSITIF D'ÉLIMINATION D'ADN ACELLULAIRE CIRCULANT
Applicants **
SANTERSUS AG
c/o Lex Futura AG
Buckhauserstrasse 34
8048 Zürich, CH
Inventors
SURKOV, Kirill
Ul. Dekabristov, D. 54, Kv. 17
St. Petersburg 190121, RU
ASWANI, Andrew
13 Sutton Court Rd, Chiswick
London W4 4NN, GB
Priority Data
63/294,024
27.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2237 | |
| EPO | Filing, Examination | 10363 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 4360 |
Total: 18121 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention provides apheresis devices and their use for substantial removal of all types of cfDNA for treatment of various diseases and during perfusion of an organ and/or anatomical cavity, to limit the negative effects of circulating cfDNA during organ transplantation and thus improve the quality and survival of transplanted organs, and reduce unfavorable transplantation outcomes such as transplant dysfunction, ischemia-reperfusion injury, graft rejection, and organ failure.[French]
L'invention concerne des dispositifs d'aphérèse et leur utilisation pour l'élimination substantielle de tous les types d'ADNcf pour le traitement de diverses maladies et pendant la perfusion d'un organe et/ou d'une cavité anatomique, pour limiter les effets négatifs de l'ADNcf circulant pendant une transplantation d'organes et améliorer ainsi la qualité et la survie d'organes transplantés, et réduire des résultats de transplantation défavorables tels qu'un dysfonctionnement de greffe, une lésion d'ischémie-reperfusion, un rejet de greffe et une défaillance d'organe.